Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (10)

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2018

  1. Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer

    Biochemical Pharmacology, Vol. 157, pp. 285-293

2016

  1. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer

    Oncotarget, Vol. 7, Núm. 30, pp. 47565-47575

  2. Anticancer mechanisms of cannabinoids

    Current Oncology, Vol. 23, pp. S23-S32

2015

  1. Endocannabinoids and cancer

    Handbook of Experimental Pharmacology (Springer New York LLC), pp. 449-472

  2. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation

    Cell Death and Differentiation, Vol. 22, Núm. 1, pp. 131-144

  3. Role of cannabinoid receptor CB<inf>2</inf> in HER2 pro-oncogenic signaling in breast cancer

    Journal of the National Cancer Institute, Vol. 107, Núm. 6

  4. TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling

    Molecular and Cellular Oncology, Vol. 2, Núm. 3

2014

  1. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling

    Journal of Biological Chemistry, Vol. 289, Núm. 32, pp. 21960-21972